ArticleObesity (Silver Spring, Md.)2026
Reduced-Frequency GLP1 Therapy Maintains Weight, Body Composition, and Metabolic Syndrome Improvements: A Case Series.
Article in Obesity (Silver Spring, Md.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Adaptive maintenance after incretin-induced weight loss: Moving beyond the continue-or-stop paradigm.Obesity pillars · 2026Article
- Early Weight Regain After GLP-1 Receptor Agonist Discontinuation: Mechanisms and Implications for Treatment De-Escalation Strategies.Diabetes, obesity & metabolism · 2026Review
- A survey of primary care physicians' views on supporting patients who lose insurance coverage for Glucagon-Like Peptide-1-based drugs for weight management.Obesity pillars · 2026Article
- GLP-1 Receptor Agonist Use in Cancer Survivors-Challenges and Opportunities: A Narrative Review.Cancers · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveThis study aimed to evaluate whether reduced-frequency dosing of GLP1 receptor agonists maintains weight loss, body composition, and metabolic syndrome improvements following successful initial treatment with standard weekly therapy.
methodsThis retrospective case series included 30 adults who achieved weight plateau while on weekly semaglutide or tirzepatide. Patients transitioned to reduced-frequency dosing (usually every other week) at their existing dose. Data were collected at three time points: pre-treatment, plateau (weekly dosing), and maintenance (reduced-frequency dosing). Primary outcome was change in body weight from plateau to maintenance. Secondary outcomes included body composition and metabolic syndrome comorbidities.
resultsPatients maintained reduced-frequency dosing for an average of 36.3 weeks. Weight decreased from 87.9 ± 2.4 kg at pre-treatment to 74.1 ± 2.4 kg at plateau and further to 72.4 ± 2.2 kg on maintenance dosing (p < 0.01). Total body and truncal fat declined, while skeletal muscle mass stabilized on the reduced-frequency regimen. Metabolic parameters improved during weekly dosing and these gains were maintained during reduced-frequency therapy.
conclusionsIn patients with prior weight loss and metabolic improvement on GLP1 therapy, reduced-frequency maintenance dosing preserved outcomes. These findings support structured de-escalation as a promising strategy to reduce treatment burden without sacrificing efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.